Oh, Jiwon http://orcid.org/0000-0001-5519-6088
Capezzuto, Luca http://orcid.org/0000-0002-2186-2406
Kriara, Lito http://orcid.org/0000-0002-9159-0469
Schjodt-Eriksen, Jens
van Beek, Johan http://orcid.org/0000-0002-5641-0004
Bernasconi, Corrado http://orcid.org/0000-0002-1019-5468
Montalban, Xavier http://orcid.org/0000-0002-0098-9918
Butzkueven, Helmut http://orcid.org/0000-0003-3940-8727
Kappos, Ludwig http://orcid.org/0000-0003-4175-5509
Giovannoni, Gavin
Bove, Riley http://orcid.org/0000-0002-2034-8800
Julian, Laura http://orcid.org/0000-0001-5699-302X
Baker, Mike http://orcid.org/0000-0002-6854-0375
Gossens, Christian http://orcid.org/0000-0003-2660-5895
Lindemann, Michael http://orcid.org/0000-0003-1010-3890
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd
Article History
Received: 4 November 2022
Accepted: 6 December 2023
First Online: 2 January 2024
Competing interests
: The authors declare the following competing financial interests and no competing non-financial interests: J Oh has received personal compensation for consulting or speaking from EMD Serono, Sanofi-Genzyme, Biogen Idec., F. Hoffmann-La Roche Ltd., Celgene, and Novartis; and has received research funding from the MS Society of Canada, National MS Society, Brain Canada, Biogen Idec., and Sanofi-Genzyme. L Capezzuto is an employee of F. Hoffmann-La Roche Ltd. L Kriara is an employee of F. Hoffmann-La Roche Ltd. J Schjodt-Eriksen is an employee of and shareholder in F. Hoffmann-La Roche Ltd. J van Beek is an employee of Biogen Inc. C Bernasconi received consulting fees as a contractor for F. Hoffmann-La Roche Ltd. during the execution of this work. X Montalban has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials, or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Genzyme, Immunic, MedDay, Merck, Mylan, Nervgen, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceuticals, TG Therapeutics, Excemed, MSIF, and NMSSH. H Butzkueven’s institution (Monash University) has received funding from Biogen, F. Hoffmann-La Roche Ltd., Merck, and Novartis; has carried out contracted research for Novartis, Merck, F. Hoffmann-La Roche Ltd., and Biogen; has taken part in speaker’s bureaus for Biogen, Genzyme, F. Hoffmann-La Roche Ltd., and Merck; and has received personal grants from Oxford Pharmagenesis and Biogen. L Kappos’ institutions (University Hospital Basel/Stiftung Neuroimmunology and Neuroscience Basel) have received and used exclusively for research support payments for steering committee and advisory board participation, consultancy services, and participation in educational activities from: Actelion, Aurigia Vision AG, Bayer, Bristol Myers Squibb, df-mp Molnia & Pohlmann, Celgene, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Japan Tobacco, Merck, MH Consulting, Minoryx, Novartis, Österreichische Gesellschaft für Neurologie, F. Hoffmann-La Roche Ltd., Senda Biosciences Inc., Sanofi, Santhera, Shionogi BV, TG Therapeutics, and Wellmera; and license fees for Neurostatus-UHB products; grants from Novartis, Innosuisse, and F. Hoffmann-La Roche Ltd. G Giovannoni received personal compensation in the past for serving as a consultant for AbbVie, Actelion, Atara Bio, Biogen, Celgene, Sanofi-Genzyme, Genentech, GlaxoSmithKline, Merck-Serono, Novartis, Roche, and Teva Pharmaceuticals; has received personal compensation from Elsevier for serving as an editor on <i>MSARDs</i>; and has received financial support for research activities from Biogen, Roche, Merck, Merck-Serono, Novartis, Sanofi-Genzyme, and Takeda. R Bove has received consultancy fees from Alexion, Biogen, EMD Serono, F. Hoffmann-La Roche Ltd., Genentech, Horizon, Janssen, Novartis, Sanofi-Genzyme, and TG Therapeutics; and is funded by the NMSS Harry Weaver Award, NIH, DOD, and NSF, as well as Biogen, Novartis, F. Hoffmann-La Roche Ltd. and Genentech. L Julian is an employee of Genentech, Inc., and a shareholder in F. Hoffmann-La Roche Ltd. M Baker is an employee of and shareholder in F. Hoffmann-La Roche Ltd. C Gossens is an employee of and shareholder in F. Hoffmann-La Roche Ltd. M Lindemann is a consultant for F. Hoffmann-La Roche Ltd. via Inovigate.